Dermatology

Understanding Familial Melanoma and FAMMM Syndrome

At a Glance

Familial melanoma and FAMMM syndrome are hereditary conditions that increase the risk of developing melanoma, often linked to the CDKN2A gene. Having a genetic mutation does not guarantee you will get cancer. Early, specialized skin screening and strict sun protection are key to prevention.

Learning that your family may have a genetic predisposition to melanoma can feel overwhelming. It is natural to feel a sense of fear or responsibility for your family’s health. However, understanding the difference between a genetic “tendency” and a “guarantee” is the first step in taking control of your health journey.

Defining Familial Melanoma

Familial melanoma is a term used when multiple members of the same family develop melanoma, suggesting a shared genetic link ^[1]. While most melanomas are sporadic—meaning they are caused by environmental factors like UV exposure and occur by chance—about 10% of cases are considered familial ^[2].

Unlike sporadic melanoma, which is driven by mutations your skin cells acquire over your lifetime, familial melanoma is often linked to germline mutations ^[3]. These are genetic changes you are born with that exist in every cell of your body and can be passed down to the next generation ^[4].

What is FAMMM Syndrome?

FAMMM syndrome (Familial Atypical Multiple Mole Melanoma) is a specific type of hereditary melanoma ^[5]. It is generally defined by three main features:

A high number of nevi (moles), often more than 50 ^[5]^[6].
Moles that look “atypical” or “dysplastic” under a microscope (meaning they have irregular borders or colors) ^[5].
A family history of melanoma in one or more close relatives ^[5].

The most common genetic cause of FAMMM syndrome is a mutation in the CDKN2A gene ^[7]^[8]. This gene normally acts as a “brake” on cell growth; when it is mutated, the brake doesn’t work as well, making it easier for cells to turn into cancer ^[2].

The Role of Moles and Genes

Having a high nevus count (many moles) is a strong risk factor for melanoma, but it is not the only factor. Researchers have identified two different pathways:

The Nevi-Related Pathway: Some people develop melanoma because they have a very high number of moles, which are influenced by a mix of many “low-impact” genes and sun exposure ^[9].
The Nevi-Resistant Pathway: Some people with a high-risk gene mutation, like CDKN2A, may develop melanoma even if they do not have many moles ^[9].

This is why clinical guidelines recommend that anyone with 60 or more moles, OR a known family mutation, should receive specialized skin monitoring ^[10].

Risk is Not Destiny

It is crucial to remember that carrying a high-risk gene mutation does not mean you are guaranteed to get cancer. Rather, it means your “baseline” risk is higher than the average person’s. In families with the CDKN2A mutation, the risk of developing melanoma over a lifetime is high, but many people with the mutation never develop the disease ^[2]^[8].

Furthermore, having this information is a tool for prevention. Families with these risks benefit from:

Daily UV Protection: While genetics play a major role, UV exposure from the sun is a critical “modifier” that can increase your risk ^[11]. Strict sun safety—including daily use of broad-spectrum SPF 30+ sunscreen, wearing UPF-rated clothing, and avoiding peak UV hours—is a vital, everyday action you can take to protect yourself.
Total Body Photography: Taking high-resolution photos of your skin to track changes in moles over time ^[12]^[13].
Dermoscopy: A specialized tool doctors use to look deep into the structure of a mole ^[14].
Other Screenings: Because some melanoma genes (like CDKN2A or BAP1) can also be linked to other cancers, such as pancreatic or eye cancer, your care team may recommend additional specialized monitoring ^[15]^[16].

Why This Matters for Your Family

Understanding your genetic status allows you to protect the next generation. If a mutation is identified, your relatives can start skin screenings earlier, which is the most effective way to catch melanoma when it is most treatable ^[17]^[14]. In some cases, patients with familial melanoma have even shown better survival rates because their cancers are caught so early through frequent screening ^[18]^[19].

Common questions in this guide

What is FAMMM syndrome?

FAMMM syndrome stands for Familial Atypical Multiple Mole Melanoma. It is a hereditary condition characterized by having a high number of moles, moles that look atypical or irregular under a microscope, and a family history of melanoma.

Does having a high mole count mean I have a genetic mutation?

Not necessarily. While having over 50 moles is a strong risk factor for melanoma, it is often influenced by a combination of low-impact genes and sun exposure. However, it can sometimes indicate a high-risk genetic mutation, which is why specialized skin monitoring is recommended.

If I have the CDKN2A mutation, will I definitely get melanoma?

No, carrying a high-risk gene mutation like CDKN2A does not guarantee you will develop cancer. It simply means your baseline risk is higher than average, making early screening and daily sun protection essential tools for managing your health.

At what age should my children or family members start skin exams?

If a genetic mutation or strong family history of melanoma is identified, relatives should begin specialized skin screenings early. Discuss your family history with a dermatologist or genetic counselor to determine the best age and schedule for your children and other relatives.

Curated prompts to bring to your next appointment.

1.Based on my family history, do I meet the clinical criteria for FAMMM syndrome?
2.Does having a high nevus count mean I have a genetic mutation, or are these separate risk factors?
3.If I test positive for a CDKN2A mutation, what is my statistical lifetime risk of developing melanoma versus pancreatic cancer?
4.How frequently should my family members be screened, and at what age should my children start skin exams?
5.Are there specific features of my nevi that make them more concerning than 'typical' moles?

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References (19)

1
Germline mutations predisposing to melanoma and associated malignancies and syndromes: a narrative review.
López Riquelme I, Martínez García S, Serrano Ordónez A, Martínez Pilar L
International journal of dermatology 2025; (64(6)):1027-1041 doi:10.1111/ijd.17602.
PMID: 39651613
2
Genetic Alterations in the INK4a/ARF Locus: Effects on Melanoma Development and Progression.
Ming Z, Lim SY, Rizos H
Biomolecules 2020; (10(10)) doi:10.3390/biom10101447.
PMID: 33076392
3
Cell Senescence and the Genetics of Melanoma Development.
Constantinou SM, Bennett DC
Genes, chromosomes & cancer 2024; (63(10)):e23273 doi:10.1002/gcc.23273.
PMID: 39422311
4
POT1 germline mutations but not TERT promoter mutations are implicated in melanoma susceptibility in a large cohort of Spanish melanoma families.
Potrony M, Puig-Butille JA, Ribera-Sola M, et al.
The British journal of dermatology 2019; (181(1)):105-113 doi:10.1111/bjd.17443.
PMID: 30451293
5
Familial atypical multiple mole melanoma syndrome in an adult Indian male-case report and literature review.
Raj RC, Patil R
Indian journal of dermatology 2015; (60(2)):217 doi:10.4103/0019-5154.152585.
PMID: 25814760
6
Development of esophageal squamous cell cancer in patients with FAMMM syndrome: Two clinical reports.
van der Wilk BJ, Noordman BJ, Atmodimedjo PN, et al.
European journal of medical genetics 2020; (63(3)):103840 doi:10.1016/j.ejmg.2020.103840.
PMID: 31923587
7
Well-differentiated Pancreatic Neuroendocrine Tumor in a Patient With Familial Atypical Multiple Mole Melanoma Syndrome (FAMMM).
Noë M, Hackeng WM, de Leng WWJ, et al.
The American journal of surgical pathology 2019; (43(9)):1297-1302 doi:10.1097/PAS.0000000000001314.
PMID: 31261289
8
CDKN2A Gene Mutations: Implications for Hereditary Cancer Syndromes.
Danishevich A, Bilyalov A, Nikolaev S, et al.
Biomedicines 2023; (11(12)) doi:10.3390/biomedicines11123343.
PMID: 38137564
9
The Interplay between Nevi and Melanoma Predisposition Unravels Nevi-Related and Nevi-Resistant Familial Melanoma.
Pellegrini S, Elefanti L, Dall'Olmo L, Menin C
Genes 2021; (12(7)) doi:10.3390/genes12071077.
PMID: 34356093
10
Indications for Digital Monitoring of Patients With Multiple Nevi: Recommendations from the International Dermoscopy Society.
Russo T, Piccolo V, Moscarella E, et al.
Dermatology practical & conceptual 2022; (12(4)):e2022182 doi:10.5826/dpc.1204a182.
PMID: 36534527
11
Characterization of Potential Melanoma Predisposition Genes in High-Risk Brazilian Patients.
Soares de Sá BC, Moredo LF, Torrezan GT, et al.
International journal of molecular sciences 2023; (24(21)) doi:10.3390/ijms242115830.
PMID: 37958811
12
Hereditary melanoma: Update on syndromes and management: Genetics of familial atypical multiple mole melanoma syndrome.
Soura E, Eliades PJ, Shannon K, et al.
Journal of the American Academy of Dermatology 2016; (74(3)):395-407; quiz 408-10.
PMID: 26892650
13
Phenotypic and Dermoscopic Patterns of Familial Melanocytic Lesions: A Pilot Study in a Third-Level Center.
Roccuzzo G, Giordano S, Granato T, et al.
Cancers 2023; (15(15)) doi:10.3390/cancers15153772.
PMID: 37568588
14
Surveillance, CDKN2A and survival of familial melanoma.
van Doorn R
Journal of the European Academy of Dermatology and Venereology : JEADV 2023; (37(2)):218-219 doi:10.1111/jdv.18796.
PMID: 36640377
15
CDKN2A/CDK4 status in Brazilian patients meeting clinical criteria for hereditary melanoma: a cross-sectional descriptive trial.
Arnaut JRMB, Guimarães IDS, Dos Santos ACE, et al.
International journal of dermatology 2023; (62(8)):1060-1066 doi:10.1111/ijd.16742.
PMID: 37322831
16
Familial Melanoma and Susceptibility Genes: A Review of the Most Common Clinical and Dermoscopic Phenotypic Aspect, Associated Malignancies and Practical Tips for Management.
Zocchi L, Lontano A, Merli M, et al.
Journal of clinical medicine 2021; (10(16)) doi:10.3390/jcm10163760.
PMID: 34442055
17
Unveiling the genetic landscape of hereditary melanoma: From susceptibility to surveillance.
Zheng C, Sarin KY
Cancer treatment and research communications 2024; (40()):100837 doi:10.1016/j.ctarc.2024.100837.
PMID: 39137473
18
Solar Lentigines are Associated with Better Outcome in Cutaneous Melanoma.
Marasigan V, Güvenç C, Oord JJ, et al.
Acta dermato-venereologica 2019; (99(12)):1154-1159 doi:10.2340/00015555-3270.
PMID: 31314121
19
Two Japanese families with familial pancreatic cancer with suspected pathogenic variants of CDKN2A: a case report.
Kiyozumi Y, Matsubayashi H, Todaka A, et al.
Hereditary cancer in clinical practice 2024; (22(1)):11 doi:10.1186/s13053-024-00283-7.
PMID: 38961426

This page provides educational information about familial melanoma and FAMMM syndrome. Always consult a dermatologist or genetic counselor to discuss your personal and family risk factors.

Get notified when new evidence is published on Familial melanoma.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

Guide Contents